ABSTRACT
BACKGROUND Life’s Essential 8 (LE8) is an important indicator to assess cardiovascular health (CVH), yet its association with ischemic stroke (IS) remains unclear. We aimed to investigate the association of LE8 with IS, as well as the underlying inflammatory mechanisms. Furthermore, we also aimed to explore whether genetic susceptibility moderated this association.
METHODS A total of 202,215 participants aged 40-69 from the UK Biobank were analyzed between 2006 and 2010, with follow-up conducted until 2022. The American Heart Association’s LE8 framework was used to calculate the LE8 scores. The link between LE8 scores and IS risk was assessed using Cox proportional hazards models. 1000 non-parametric bootstrapping simulations were used to calculate the mediation effect. CVH levels and genetic susceptibility were classified as high, medium, and low based on their LE8 scores and polygenetic risk scores (PRS), respectively.
RESULTS 2,515 individuals experienced IS over a median follow-up period of 13.73 years. In comparison to the low CVH group, the medium CVH group exhibited a 26% reduction in the risk of IS (HR 0.74; 95% CI, 0.65-0.80), while the high CVH group demonstrated a 53% reduction (HR 0.47; 95% CI, 0.39-0.57). An increased LE8 scores were inversely correlated with the risk of IS (HR: 0.84; 95% CI: 0.80-0.87), partially mediated by inflammatory markers. According to the joint effect analysis, individuals with low genetic susceptibility and high CVH had the lowest IS risk (HR: 0.20; 95% CI: 0.13-0.30) when compared to those with genetic susceptibility and low CVH.
CONCLUSIONS The findings imply that higher LE8 scores and CVH levels are associated with a lower incidence of IS, partially mediated by inflammatory markers. This protective relationship can be strengthened in cases of lower genetic susceptibility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was not any external financing for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North-West Multi-Centre Research Ethics Committee approved the UK Biobank study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data availability The data supporting the findings of this study are available in the UK Biobank repository. Accessible at: https://www.ukbiobank.ac.uk.
- IS
- ischemic stroke
- CVH
- cardiovascular health
- AHA
- American Heart Association
- LS7
- Life’s Simple 7
- non-HDL
- non-high-density lipoprotein
- CRP
- C-reactive protein
- ICD-10
- tenth International Classification of Diseases
- WBC
- white blood cell
- GrL
- granulocyte/lymphocyte ratio
- PRS
- polygenic risk scores
- GWAS
- genome-wide association study
- AIC
- Akaike Information Criterion
- RERI
- relative excess risk
- AP
- attributable proportion
- ROS
- reactive oxygen species
